Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
This rigorous methodology minimizes bias and allows for accurate attribution of adverse effects to the intervention rather than background health conditions or placebo effects
S., Kang, L
While the FDAs recent actions underscore its commitment to ensuring drug safety and efficacy, the ongoing demand for affordable and accessible weight management solutions highlights the need for clearer guidance and innovation
Now, two new late-phase clinical trials, sponsored by Eli Lilly and Company, suggest that transitioning from high dose injectable weight loss medications to either a daily pill or a lower maintenance dose can help people living with obesity to keep off most of the weight they have already lost The results of the ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN trials were presented at the European Congress on Obesity and published in Previous research suggests that 1 year after stopping weight loss medication, people may regain, on average, 60% of their lost weight
